Neuro-symbolic, multi-agent AI system achieves 4x faster trial matching with oncologist-confirmed accuracy across 17,000+ matches, published in ESMO Real World Data and Digital Oncology special issue ...
Just Worldwide will utilise its engagement infrastructure to increase awareness of Massive Bio's clinical trials.
CHICAGO--(BUSINESS WIRE)--Massive Bio, a global company specializing in AI-powered clinical trial matching and oncology data solutions, is participating in the 2025 American Society of Clinical ...
Taletrectinib is an oral, potent, central nervous system-active, selective, next-generation ROS1 inhibitor specifically designed for the treatment of patients with advanced ROS1+ NSCLC. Taletrectinib ...
Massive Bio, a cancer patient matchmaker, has been selected by the Precision Cancer Consortium to help identify potential candidates for clinical trials. The consortium, founded in 2022, is focused on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results